Complete Response Letter Issued to Eflapegrastim for Chemotherapy-Induced Neutropenia Indication

Article

The makers of eflapegrastim received a complete response letter from the FDA due to concerns over manufacturing.

A biologics license application for the novel long-acting granulocyte-colony stimulating factor (G-CSF) agent eflapegrastim (Rolontis) was issued a complete response letter by the FDA due to deficiencies in manufacturing, as reported by the company responsible for the agent, Spectrum Pharmaceuticals.1

The FDA indicated that a reinspection will be necessary and further clarification regarding these plans are being discussed between the 2 entities.

“We are disappointed with this outcome and look forward to fully understanding the remediation timelines for the program,” Joe Turgeon, president and CEO of Spectrum Pharmaceuticals, said in a press release. “We continue to believe in Rolontis and plan to diligently complete the regulatory process to bring Rolontis to market.”

Eflapegrastim is intended for use alongside myelosuppressive anticancer drugs and, if approved, would be the first novel G-CSF agent to become available to clinicians and their patients in over a decade. The BLA was supported by data from 2 phase 3 clinical trials investigating the safety and efficacy of the agent in patients with early-stage breast cancer receiving chemotherapy for their disease.

In the ADVACNE trial (NCT02643420), eflapegrastim was compared with pegfilgrastim in patients with early breast cancer who were receiving docetaxel and cyclophosphamide with a primary end point of severe neutropenia duration in cycle 1. In 406 patients in the intent-to-treat population, the mean duration of severe neutropenia (DSN) was 0.19 days (standard deviation [SD], 0.478) in the experimental arm vs 0.34 days (SD, 0.668) with pegfilgrastim and met the threshold for non-inferiority (95% CI, -0.260 to -0.035; P <.0001). Noninferiority was maintained across all 4 cycles.2

The RECOVER trial (NCT02953340) was conducted in a similar fashion to ADVANCE in 237 intent to treat patients, for which the mean DSN was 0.31 days (SD, 0.688) for eflapegrastim compared with 0.39 days (SD, 0.949) with standard pegfilgrastim (95% CI, -0.292 to 0.129; P <.0001), with noninferiority maintained across 4 cycles of therapy.3

In either trial, the statistical significance for additional end points such as time to absolute neutrophil count (ANC) recovery, depth of ANC nadir, and incidence of febrile neutropenia at cycle 1 were noted.

This BLA for eflapegrastim was initially submitted in October 2019, which was an update to a previously withdrawn application for this indication. The new BLA had additional information in the Chemistry, Manufacturing and Controls (CMC) section regarding the manufacturing process.4 In December 2019, the company announced that the new BLA had been accepted by the FDA with a prescription drug user fee act (PDUFA) date of October 24, 2020.5

References

1. Spectrum Pharmaceuticals receives complete response letter from FDA for Rolontis (eflapegrastim). News release. Spectrum Pharmaceuticals. August 6, 2021. Accessed August 6, 2021. https://bit.ly/3AiXbj2

2. Schwartzberg LS, Yang Z, Peguero JA, et al. Safety and efficacy of eflapegrastim in reducing severe neutropenia in patients treated with myelosuppressive chemotherapy in a phase 3 randomized controlled trial compared to pegfilgrastim (ADVANCE trial). J Clin Oncol. 2018;36(suppl 15):e12513. doi:10.1200/JCO.2018.36.15_suppl.e12513

3. Schwartzberg LS, Bhat G, Mezei K, et al. Efficacy and safety of eflapegrastim confirmed in reducing severe neutropenia in breast cancer patients treated with myelosuppressive chemotherapy in the second phase 3 randomized controlled multinational trial compared to pegfilgrastim (RECOVER trial). Cancer Res. 2019;79(suppl 4):P1-13-05. doi: 10.1158/1538-7445.SABCS18-P1-13-05.

4. Spectrum Pharmaceuticals announces submission to the U.S. Food and Drug Administration of updated biologics license application for Rolontis. News release. Spectrum Pharmaceuticals. Published October 24, 2019. Accessed August 6, 2021. https://bit.ly/3fDAhv0

5. Spectrum Pharmaceuticals provides pipeline update on late stage programs. News release. Spectrum Pharmaceuticals. Published December 26, 2019. Accessed August 6, 2021. https://bit.ly/2VtM8EF

Recent Videos
The Together for Supportive Cancer Care coalition may advance the national conversation in ensuring comprehensive care for all patients with cancer.
Health care organizations have come together to form the Together for Supportive Cancer Care coalition to address gaps in supportive cancer care services.
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Related Content
Patients who start smoking cessation treatment after cancer diagnosis are found to have higher rates of survival.

Smoking Cessation Treatment Yields Greater Survival After Cancer Diagnosis

Tim Cortese
November 10th 2024
Article

Patients who start smoking cessation treatment after cancer diagnosis are found to have higher rates of survival.

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation

Jessica Cheng, MD
September 9th 2024
Podcast

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Gender Equity in Hematology/Oncology Have We Made Any Progress?

Gender Equity in Hematology/Oncology Have We Made Any Progress?

Julie M. Vose, MD, MBA
November 6th 2024
Article

Julie M. Vose, MD, MBA, highlights the push toward gender diversity in medical oncology.

Cancer vaccines may pair well with other forms of immunotherapy in the treatment of patients with cancer, according to Catherine J. Wu, MD.

Taking a “Cross-Cutting Approach” With Cancer Vaccinations

Catherine J. Wu, MD
August 12th 2024
Podcast

Cancer vaccines may pair well with other forms of immunotherapy in the treatment of patients with cancer, according to Catherine J. Wu, MD.

Data presented from a pilot study evaluating HERC validated its usability in measuring equitable practices at leading cancer centers.

HERC Tool Demonstrates Feasibility in Advancing Equitable Cancer Care

Roman Fabbricatore
October 29th 2024
Article

Data presented from a pilot study evaluating HERC validated its usability in measuring equitable practices at leading cancer centers.

Findings from 3 studies combining birth and cancer registers showed postponing childbearing partially correlated with cancer increases in pregnant women.

Maternal Risks Appear Low Despite Increases in Cancer During Pregnancy

Roman Fabbricatore
October 26th 2024
Article

Findings from 3 studies combining birth and cancer registers showed postponing childbearing partially correlated with cancer increases in pregnant women.